Results 231 to 240 of about 17,484,371 (316)

T-bet⁺CD8⁺ T cells govern anti-PD-1 responses in microsatellite-stable gastric cancers. [PDF]

Nat Commun
Tang S, Che X, Wang J, Li C, He X, Hou K, Zhang X, Guo J, Yang B, Li D, Cao L, Qu X, Wang Z, Liu Y.   +13 more
europepmc   +1 more source

Transfer of mesenchymal stem cell mitochondria to CD4⁺ T cells contributes to repress Th1 differentiation by downregulating T-bet expression. [PDF]

Stem Cell Res Ther, 2023
Akhter W, Nakhle J, Vaillant L, Garcin G, Le Saout C, Simon M, Crozet C, Djouad F, Jorgensen C, Vignais ML, Hernandez J.   +10 more
europepmc   +1 more source

LDAcoop: Integrating non‐linear population dynamics into the analysis of clonogenic growth in vitro

Molecular Oncology, EarlyView.
Limiting dilution assays (LDAs) quantify clonogenic growth by seeding serial dilutions of cells and scoring wells for colony formation. The fraction of negative wells is plotted against cells seeded and analyzed using the non‐linear modeling of LDAcoop.
Nikko Brix, Daniel Samaga, Katharina Gehr, Benedek Dankó, Mohamed Schumann, Guido Drexler, Ahmed Alnatsha, Georg Beyer, Ujjwal Mahajan, Martin Selmansberger, Julia Mayerle, Claus Belka, Horst Zitzelsberger, Kirsten Lauber   +13 more
wiley   +1 more source

Mycobacterium tuberculosis-Specific CD4 T Cells Expressing Transcription Factors T-Bet or RORγT Associate with Bacterial Control in Granulomas. [PDF]

mBio, 2023
Grant NL, Kelly K, Maiello P, Abbott H, O'Connor S, Lin PL, Scanga CA, Flynn JL.   +7 more
europepmc   +1 more source

Plecstatin inhibits hepatocellular carcinoma tumorigenesis and invasion through cytolinker plectin

Molecular Oncology, EarlyView.
The ruthenium‐based metallodrug plecstatin exerts its anticancer effect in hepatocellular carcinoma (HCC) primarily through selective targeting of plectin. By disrupting plectin‐mediated cytoskeletal organization, plecstatin inhibits anchorage‐dependent growth, cell polarization, and tumor cell dissemination.
Zuzana Outla, Jan Kosla, Magdalena Prechova, Lukas Frick, Patricia Bortel, Yasmin Borutzki, Andrea Bileck, Christopher Gerner, Samuel M. Meier‐Menches, Selma Osmanagic‐Myers, Martin Gregor   +10 more
wiley   +1 more source

Characterization of T-bet expressing B cells in lupus patients indicates a putative prognostic and therapeutic value of these cells for the disease. [PDF]

Clin Exp Immunol
Sachinidis A, Trachana M, Taparkou A, Gavriilidis G, Vasileiou V, Keisaris S, Verginis P, Adamichou C, Boumpas D, Psomopoulos F, Garyfallos A.   +10 more
europepmc   +1 more source

Cross-Regulation of F-Box Protein FBXL2 with T-bet and TNF-α during Acute and Chronic Lung Allograft Rejection. [PDF]

J Immunol, 2022
Das A, Wang X, Wei J, Hoji A, Coon TA, Popescu I, Brown M, Frizzell S, Iasella CJ, Noda K, Sembrat JC, Devonshire K, Hannan SJ, Snyder ME, Pilewski JM, Sanchez PG, Chandra D, Mallampalli RK, Alder JK, Chen BB, McDyer JF.   +20 more
europepmc   +1 more source

The evolving role of T-bet in resistance to infection

Nature reviews. Immunology, 2019
G. Pritchard, R. Kedl, C. Hunter
semanticscholar   +1 more source

Recurrent cancer‐associated ERBB4 mutations are transforming and confer resistance to targeted therapies

Molecular Oncology, EarlyView.
We show that the majority of the 18 analyzed recurrent cancer‐associated ERBB4 mutations are transforming. The most potent mutations are activating, co‐operate with other ERBB receptors, and are sensitive to pan‐ERBB inhibitors. Activating ERBB4 mutations also promote therapy resistance in EGFR‐mutant lung cancer.
Veera K. Ojala, Sini Ahonen, Sara Peltola, Aura Tuohisto‐Kokko, Olaya Esparta, Peppi Suominen, Anne Jokilammi, Iman Farahani, Deepankar Chakroborty, Nikol Dibus, Steffen Boettcher, Tomi T. Airenne, Mark S. Johnson, Lisa D. Eli, Klaus Elenius, Kari J. Kurppa   +15 more
wiley   +1 more source

Global deletion of the immune cell transcription factor, T-bet, alters gut microbiota and insulin sensitivity in mice. [PDF]

Front Genet
Stolarczyk E, Vong CT, Garrido-Mesa N, Marks E, Abdel-Aziz D, Ju Q, Jackson I, Powell N, Lord GM, Howard JK.   +9 more
europepmc   +1 more source